Human cytomegalovirus infection in tumor cells of the nervous system is not detectable with standardized pathologico-virological diagnostics

Neuro-Oncology

Volumn 16, Issue 11, 2014, Pages 1469-1477

  Baumgarten, Peter ^a   Michaelis, Martin ^a,c   Rothweiler, Florian ^a   Starzetz, Tatjana ^a   Rabenau, Holger F ^a   Berger, Annemarie ^a   Jennewein, Lukas ^a   Braczynski, Anne K ^a   Franz, Kea ^a   Seifert, Volker ^a   Steinbach, Joachim P ^a,b   Allwinn, Regina ^a   Mittelbronn, Michel ^a,b   Cinatl, Jindrich ^a  

^a GOETHE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF KENT   (United Kingdom)

Author keywords

Cytomegalovirus; Glioma; Oncomodulation

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; GENOMIC DNA; VIRUS ANTIGEN; VIRUS DNA;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER EPIDEMIOLOGY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; HUMAN CYTOMEGALOVIRUS INFECTION; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MEDULLOBLASTOMA; NERVOUS SYSTEM; NERVOUS SYSTEM TUMOR; NEUROBLASTOMA; NEUROBLASTOMA CELL; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; STANDARDIZATION; SURVIVAL RATE; TUMOR CELL; VIRUS EXAMINATION; VIRUS STRAIN; WESTERN HEMISPHERE; BRAIN NEOPLASMS; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; MORTALITY; PROGNOSIS; VERY ELDERLY; VIROLOGY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROBLASTOMA; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; SEROEPIDEMIOLOGIC STUDIES; SURVIVAL RATE;

EID: 84924974139     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou167     Document Type: Article

References (36)

1. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010;20(4):202-213.
2. Sinclair J. Human cytomegalovirus: latency and reactivation in the myeloid lineage. J Clin Virol. 2008;41:180-185.
3. Mocarski ES, Shenk T, Pass RF. Cytomegaloviruses. In: Knipe DM, Howley PM, eds. Fields Virology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007: 2701-2772.
4. Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA. 2008;300:413-422.
5. Cinatl J Jr, Cinatl J, Vogel JU, et al. Modulatory effects of human cytomegalovirus infection on malignant properties of cancer cells. Intervirology. 1996;39(4):259-269.
6. Michaelis M, Doerr HW, Cinatl J Jr. The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia. 2009;11:1-9.
7. Cinatl J Jr, Vogel JU, Cinatl J, et al. Long-term productive human cytomegalovirus infection of a human neuroblastoma cell line. Int J Cancer. 1996;65(1):90-96.
8. Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002;62(12):3347-3350.
9. Baryawno N, Rahbar A, Wolmer-Solberg N, et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest. 2012;121(10):4043-4055.
10. Dziurzynski K, Chang SM, Heimberger AB, et al. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol. 2012;14(3):246-255.
11. Johnsen JI, Baryawno N, Söderberg-Nauclér C. Is human cytomegalovirus a target in cancer therapy?. Oncotarget. 2011;2(12):1329-1338.
12. Soroceanu L, Cobbs CS. Is HCMV a tumor promoter?. Virus Res. 2011;157(2):193-203.
13. Wolmer-Solberg N, Baryawno N, Rahbar A, et al. Frequent detection of human cytomegalovirus in neuroblastoma: a novel therapeutic target?. Int J Cancer. 2013;133(10):2351-2361.
14. Cosset E, Petty TJ, Dutoit V, et al. Comprehensive metagenomic analysis of glioblastoma reveals absence of known virus despite antiviral-like type I interferon gene response. Int J Cancer. 2014;135(6):1381-1389.
15. Lau SK, Chen YY, Chen WG, et al. Lack of association of cytomegalovirus with human brain tumors. Mod Pathol. 2005;18(6):838-843.
16. Sabatier J, Uro-Coste E, Pommepuy I, et al. Detection of human cytomegalovirus genome and gene products in central nervous system tumors. Br J Cancer. 2005;92(4):747-750.
17. Sehic D, Forslund O, Sandén E, et al. Absence of Epstein-Barr and cytomegalovirus infection in neuroblastoma cells by standard detection methodologies. Pediatr Blood Cancer. 2013;60(9):E91-E93.
18. Tang KW, Alaei-Mahabadi B, Samuelsson T, et al. The landscape of viral expression and host gene fusion and adaptation in human cancer. Nat Commun. 2013;4:2513.
19. Yamashita Y, Ito Y, Isomura H, et al. Lack of presence of the human cytomegalovirus in human glioblastoma. Mod Pathol. 2014;27(7):922-929.
20. Preiser W, Buxbaum S, Fleckenstein C, et al. Measurement of CVM DNA levels and CMV-specific CD4+ lymphocyte counts in patient specimens: Requirements for test quality and practicality in a routine diagnostic service. In: Prösch S, Cinatl J, Scholz M, eds. New Aspects of CMV-Related Immunopathology. Karger: Basel, 2003;24:133-148.
21. Griscelli F, Barrois M, Chauvin S, et al. Quantification of human cytomegalovirus DNA in bone marrow transplant recipients by real-time PCR. J Clin Microbiol. 2001;39(12):4362-4369.
22. Michaelis M, Barth S, Breitling R, et al. Selection of a highly invasive neuroblastoma cell population through long-term human cytomegalovirus infection. Oncogenesis. 2012;1:e10.
23. Munro SC, Hall B, Whybin LR, et al. Diagnosis of and screening for cytomegalovirus infection in pregnant women. J Clin Microbiol. 2005;43(9):4713-4718.
24. Scheurer ME, Bondy ML, Aldape KD, et al. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol. 2008;116(1):79-86.
25. Bhattacharjee B, Renzette N, Kowalik TF. Genetic analysis of cytomegalovirus in malignant gliomas. J Virol. 2012;86(12):6815-6824.
26. Mitchell DA, Xie W, Schmittling R, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol. 2008;10(1):10-18.
27. Söderberg-Nauclér C. HCMV microinfections in inflammatory diseases and cancer. J Clin Virol. 2008;41:218-223.
28. Amirian ES, Marquez-Do D, Bondy ML, et al. Anti-humancytomegalovirus immunoglobulin G levels in glioma risk and prognosis. Cancer Med. 2013;2(1):57-62.
29. Lehrer S, Green S, Ramanathan L, et al. No consistent relationship of glioblastoma incidence and cytomegalovirus seropositivity in whites, blacks, and Hispanics. Anticancer Res. 2012;32(3):1113-1115.
30. Sjöström S, Hjalmars U, Juto P, et al. Human immunoglobulin G levels of viruses and associated glioma risk. Cancer Causes Control. 2011;22(9):1259-1266.
31. Söderberg-Nauclér C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med. 2013;369(10):985-986.
32. Stragliotto G, Rahbar A, Solberg NW, et al. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. Int J Cancer. 2013;133(5):1204-1213.
33. Weller M, Soffietti R, Brada M. The legend of cytomegalovirus and glioblastoma lives on. Neuro Oncol. 2013;16(1):166.
34. WickW, Wick A, Platten M. Good maths is needed to understand CMV data in glioblastoma. Neuro Oncol. 2014;16(1):165.
35. Schuessler A, Smith C, Beagley L, et al. Autologous T cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res. 2014;74(13):3466-3476.
36. Michaelis M, Baumgarten P, Mittelbronn M, et al. Oncomodulation by human cytomegalovirus: novel clinical findings open new roads. Med Microbiol Immunol. 2011;200(1):1-5.